Log in to save to my catalogue

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic can...

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic can...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2e57a0d7fd7f42d6a9f88e1c0cae6aca

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

About this item

Full title

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Publisher

England: BioMed Central Ltd

Journal title

Journal of experimental & clinical cancer research, 2021-12, Vol.40 (1), p.382-382, Article 382

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target. The core splicing factor SF3B1 is heavily altered in cancer and can be inhibited by Pladienolide-B,...

Alternative Titles

Full title

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2e57a0d7fd7f42d6a9f88e1c0cae6aca

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2e57a0d7fd7f42d6a9f88e1c0cae6aca

Other Identifiers

ISSN

1756-9966,0392-9078

E-ISSN

1756-9966

DOI

10.1186/s13046-021-02153-9

How to access this item